Bictegravir, a novel integrase inhibitor for the treatment of HIV infection

Keyphrases

• Adverse Effects 20%
• Anticonvulsant 20%
• Antiviral Activity 20%
• Antiviral Drugs 20%
• Barrier Resistance 20%
• Bictegravir 100%
• Chelation 20%
• Clinical Trials 20%
• Combination Therapy 20%
• Cytochrome P450 3A4 (CYP3A4) 40%
• Diarrhea 20%
• Drug Interactions 20%
• Drug Regimen 20%
• Emtricitabine 20%
• Fixed-dose Combination 20%
• Genetic Barrier 20%
• Glucuronidation 20%
• Headache 20%
• HIV Treatment 20%
• Inducer 20%
• Integrase Inhibitors 100%
• Integrase Strand Transfer Inhibitor (INSTI) 40%
• Nausea 20%
• Once-daily Dosing 20%
• Plasma Half-life 20%
• Polyvalent Cations 20%
• Resistance Development 20%
• Rifamycin 20%
• Suppression Ratio 20%
• Tenofovir Alafenamide 20%
• Treatment of HIV Infection 100%
• UGT1A1 40%
• Virologic Suppression 20%
• Wild Strain 20%
• Wild Type Virus 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticonvulsive Agent 20%
• Antiviral Activity 20%
• Bictegravir 100%
• Bioavailability 20%
• Clinical Trial 20%
• Combination Therapy 20%
• CYP3A4 40%
• Diarrhea 20%
• Drug-Drug Interaction 20%
• Emtricitabine 20%
• Glucuronosyltransferase 1A1 40%
• Headache 20%
• HIV 20%
• Human Immunodeficiency Virus Infection 100%
• Integrase 20%
• Integrase Inhibitor 100%
• Nausea 20%
• Rifamycin 20%
• Tenofovir Alafenamide 20%